1. Yamamoto T, Kitazawa Y. Vascular pathogenesis of normal tension glaucoma: a possible pathogenic factor, other than intraocular pressure, of glaucomatous optic neuropathy. Prog Retin Eye Res 1998;17(1):127-143.
2. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989; 107:186-188.
3. Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthal 1987;65(Suppl);S27-S29.
4. Anderson DR, Cynader MS. Glaucoma-tous optic nerve cupping as an optic neuropathy. Clin Neurosci 1997;4(5): 274-278.
5. Gasser P, Flammer J. Blood-cell velocity in the nail fold capillaries of patients with normal tension and high tension glau-coma. Am J Ophthalmol 1991;111: 585-588.
6. Graham SL, Drance SM, Wijsman K, et al. Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip. Ophthalmology 1995;102(1):61-69.
7. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypo-tension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994;117:603-642.
8. Tielsch JM, Sommer KJ, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open angle
glaucoma. A population based assess-ment. Arch Ophthalmol 1995;113: 216-221.
9. Pichot O, Gonzalvez B, Franco A, Mouillon M. Color Doppler ultrasono-graphy in the study of orbital and ocular vascular diseases. J Fr Ophthalmol 1996;19:19-31.
10. Harris A, Sergott RC, Speath GL, et al. Color doppler analysis of ocular blood vessel velocity in normal tension glau-coma. Am J Ophthalmol 1994;118:
642-649.
11. Galassi F, Nuzzaci G, Sodi A, et al. Color Doppler imaging in evaluation of optic nerve blood supply in normal and glaucomatous subjects. Int Ophthalmol 1992;16:273-276.
12. Butt Z, O'Brien C, McKillop G, et al. Color Doppler imaging in untreated high- and normal-tension open angle glaucoma. Invest Ophthalmol Vis Sci 1997;38:690-696.
|
13. Kaiser HJ, Schoetzau A, Stumpfig D, Flammer J. Blood flow velocities of the extraocular vessels in patients with high tension and normal tension primary open angle glaucoma. Am J Ophthalmol 1997;123: 320-327.
14. Collignon-Brach J. Long term effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open angle glaucoma. Surv Ophthalmol 1994;38(Suppl):S149-S155.
15. Kitazawa Y, Shirai H, Go FJ. The effect of Ca antagonist on the visual field in low tension glaucoma. Graefes Arch Clin Exp Ophthalmol 1989;227:408-412.
16. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low tension glaucoma and open angle glaucoma. Am J Ophthalmol 1993:115:608-613.
17. Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995;36:774-786.
18. Frade JM, Bololenta P, Martinez-Morales JR, et al. Control of early cell death by BDNF in chick retina. Development 1997;124:3313-3320.
19. Pienardo-Ramon R, Salvador M, Villegas-Perez MP, Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3 and BDNF on the survival of adult rat retinal ganglion cells: A quantitative in-vivo study. Inv Ophthalmol Vis Sci 1996; 37:489-500.
20. Wadia JS, Chalmers-Redman RME, Ju WJH, et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-Deprenyl. J Neurosci 1998;18:932-947.
21. Okisaka S, Murakami A, Mizukawa A, Ito J. Apoptosis in retinal ganglion cell decrease in human glaucoma eyes. Jpn J Ophthalmol 1997;41:84-88.
22. Narayanan V. Apoptosis in development of the nervous system. 1. Naturally occurring death in the developing nervous system. Pediatr Neurol 1997;16:9-13.
23. Lo AC, Houeuou LJ, Oppenheim RW. Apoptosis in the nervous system. Morphologic features, methods, pathology and prevention. Arch Histol Cytol 1995;58:139-49.
|
24. Tatton WG, Chalmers-Redman RM, et al. Apoptosis in neurodegenerative disorders: potential for therapy for modifying gene transcription. J Neurol Transm 1997;49(Suppl):S245-S268.
25. Schwartz M, Belkin M, Yoles E, Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuro-protection and neuroregeneration. J Glaucoma 1996;5:427-432.
26. Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol 1996;121: 473-483.
27. Dreyer EB, Zurakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114:299-305.
28. Tatton WG, Ju WY, Holland DP, Kwan M. (-)- Deprenyl reduces PC12 cell apop-tosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
29. Buys WM, Trobe GE, Tatton WG. (-)- Deprenyl increases the survival of retinal ganglion cells after optic nerve crush. Curr Eye Res 1995;14:119-126.
30. Osborne NN, Cajevieille C, Carvallo AC, et al. In vivo and in vitro experiments show that betaxolol is a retinal neuro-protective agent. Brain Res 1997; 751:113-123.
31. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(Suppl 1) S9-S18.
32. Klocker N, Cellerino A, Bahr M. Free radical scavenging and inhibition of nitric oxide synthase potentiates the neuro-trophic effects of brain-derived neuro-trophic factor on axotomized retinal ganglion cells in vivo. J Neurosci 1998;18:1038-1046.
33. Chew SJ, Ritch R. Neuroprotection. The next breakthrough in glaucoma? J Glaucoma 1997;6:263-266.
34. Nichols J, Samples N. Regeneration of immature mammalian spinal cord after injury. Trends Neurosci 1996;19(6): 229-234.
35. Vischer HA. BDNF is expressed at the crush site after spinal cord lesion in newborn opossums. Eur J Neurosci 1997;9:1993-1997.
|
